

#19/f
NEPATENT
Docket No. 110.00680101IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): FIELDS et al.) Group Art Unit: 1642
Serial No.: 09/529,691)
Confirmation No.: 3203)
Filed: August 29, 2000)
For: INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

In response to the Office Action mailed December 3, 2002, please amend the above-identified application as follows:

In the Specification

Please replace the paragraph beginning at page 5, line 16, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also show in Appendix A with notations to indicate the changes made.

F1
Figures 1A and 1B show the relative inhibition of M14#5 human melanoma cell adhesion to 10 µg/mL type IV collagen (TIV), fibronectin (FN), laminin (LM), or bovine serum albumin (BSA) by 100 µg/mL of L-IVH1, D-IVH1, or RI-IVH1 (a polypeptide having the sequence pro-ala-gly-pro-trp-gly-pro-asn-gly-lys-asp-gly-lys-val-gly (all L-form: SEQ ID NO:3), which is the all-D form synthesized in the reverse order and referred to as "Retro-Inverso"). Cells were preincubated with the peptides for 15 minutes and then added to the wells in the presence of the peptides for a 30-minute incubation period at 37°C. The data represent the means of triplicate points plus or minus the standard errors of the means. Figures 1A and 1B represent different experiments run under the same conditions.